eviQ and the Cancer Institute NSW have led the development of a new clinical guideline, *International consensus guideline for anticancer drug dosing in kidney dysfunction (ADDIKD)*.

**Aim of the guideline**

- Anticancer drug dosing recommendations in kidney dysfunction are often empirical, dependent on kidney function calculations based on non-standardised creatinine assays and lack applicability to globally accepted kidney dysfunction classifications.
- This guideline provides a practical, evidence-based and standardised approach to the assessment of kidney function in cancer patients and its application to anticancer drug dosing. It aims to be a decision support tool for cancer clinicians.

**Guideline development**

- ADDIKD has been developed by an international, multidisciplinary working party, which includes expert medical oncologists, haematologists, nephrologists, pharmacists, clinical pharmacologists and guideline development specialists.
- The guideline has three consensus recommendations, which provide the basis for formulating the dosing recommendations for 59 anticancer drugs.

**Consultation**

- eviQ and the Cancer Institute NSW invite interested parties to comment on the *draft guideline*.
- Consultation period will close midnight (AEST) 31st May 2022.

If you have any questions, please contact Geeta Sandhu on Geetpal.Sandhu@health.nsw.gov.au

Please scan the QR code and have your say!